Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Vijay Vashi"'
Publikováno v:
Monday, April 24.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdb3c432c63bf6d9d5ceeafa084a00d2
https://doi.org/10.1212/wnl.0000000000201801
https://doi.org/10.1212/wnl.0000000000201801
Autor:
Fumiaki Kobayashi, Tharin Limsakun, Joseph Pav, Jarema Kochan, Vijay Vashi, Ophelia Yin, Jin Zhou, George Atiee, Victor Dishy, Cynthia Zamora, Vance Warren
Publikováno v:
The Journal of Clinical Pharmacology. 59:1669-1677
DS-1040, a low-molecular-weight imidazole derivative, inhibits the enzymatic activity of thrombin-activatable fibrinolysis inhibitor (TAFIa), enhancing endogenous tissue plasminogen activator-triggered fibrinolysis. This first-in-human, randomized, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d66f33ece42310c4e25eb8ac4b8893f
https://doi.org/10.1002/jcph.1474
https://doi.org/10.1002/jcph.1474
Autor:
Naotoshi, Yamamura, Jeanne, Mendel-Harary, Karen, Brown, Minoru, Uchiyama, Yoko, Urasaki, Makoto, Takahashi, Vance, Warren, Vijay, Vashi
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 51(5)
The metabolism, excretion, and pharmacokinetics of mirogabalin were investigated following a single oral administration of [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e41b225853dd6571b6999ff5d4413bd6
https://pubmed.ncbi.nlm.nih.gov/33487061
https://pubmed.ncbi.nlm.nih.gov/33487061
Autor:
C Zamora, Y Orihashi, Ophelia Yin, Vance Warren, Jarema Kochan, Vijay Vashi, Jin Zhou, G Atiee, Victor Dishy, Joseph Pav
Publikováno v:
Journal of Thrombosis and Haemostasis. 15:961-971
Essentials DS-1040 inhibits the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa). Infusion of DS-1040 was safe and well tolerated in healthy young and elderly subjects. DS-1040 substantially decreased TAFIa activity but had no im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c287075c6f08e687c04e6cfdfb9bc50
https://doi.org/10.1111/jth.13658
https://doi.org/10.1111/jth.13658
Autor:
Victor Dishy, Takashi Taguchi, Akiko Watanabe, Vijay Vashi, Robert Bass, Jin Zhou, Kazuhito Shiosakai, Emi Kamiyama, Hidetoshi Furuie, Yusuke Myobatake, Hitoshi Ishizuka, Manabu Kato, Vance Warren, Yutaro Maekawa
Publikováno v:
Clinical drug investigation. 39(10)
Non-clinical study data suggest that DS-8500a, a G protein-coupled receptor 119 agonist, exhibits antidiabetic activity, inhibition of some transporters and induction of cytochrome P450 (CYP) 3A. Statins are substrates for some transporters and CYP3A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de0aede4e781b834bc3da5b615ba654f
https://pubmed.ncbi.nlm.nih.gov/31321631
https://pubmed.ncbi.nlm.nih.gov/31321631
Publikováno v:
The Journal of Clinical Pharmacology. 45:547-554
Hydromorphone hydrochloride extended release (HHER) is a multiparticulate melt-extrusion pellet capsule formulation administered q24h. Study 1 investigated the bioavailability of 24-mg HHER fed, as well as 24-mg and 12-mgHHER and 8-mg hydromorphone h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::755e3935ae59297032ef1aa3eb736b50
https://doi.org/10.1177/0091270005274552
https://doi.org/10.1177/0091270005274552
Publikováno v:
The Journal of Clinical Pharmacology. 40:67-73
The pharmacokinetics of doxazosin was determined in an open-label study of 12 male volunteers with hepatic impairment (stable alcoholic cirrhosis) and 12 healthy male volunteers. Participants (fasting) received a single 2 mg doxazosin tablet, and blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f02a719d9c6f4b1c21eee664228c79a
https://doi.org/10.1177/009127000004000109
https://doi.org/10.1177/009127000004000109
Publikováno v:
Urology. 53:329-335
Objectives. To investigate the relationship among doxazosin dose, plasma concentration, and clinical response in 248 hypertensive men with benign prostatic hyperplasia (BPH) in a 16-week, placebo-controlled, double-blind study. Methods. After a 2-wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88f2c72e3379880f4232ef9b12e2dbe7
https://doi.org/10.1016/s0090-4295(98)00506-8
https://doi.org/10.1016/s0090-4295(98)00506-8
Publikováno v:
The Journal of Clinical Pharmacology. 38:1072-1076
The alpha 1-adrenoceptor antagonists doxazosin and terazosin and the 5 alpha-reductase inhibitor finasteride are used in the treatment of benign prostatic hyperplasia. The aim of this study was to assess the potential pharmacokinetic interaction of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::802813ed5193568eed032c06b3875e70
https://doi.org/10.1177/009127009803801113
https://doi.org/10.1177/009127009803801113
Intravenous ampicillin-sulbactam is effective in the treatment of various infections in adults, but little is known about the pharmacokinetics (PK) of ampicillin-sulbactam in children. The objective of this study was to determine the PK of ampicillin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f59d09f140599ed62e8e48a2931df051
https://europepmc.org/articles/PMC89137/
https://europepmc.org/articles/PMC89137/
